These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22127348)

  • 41. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.
    Nichols CR; Catalano PJ; Crawford ED; Vogelzang NJ; Einhorn LH; Loehrer PJ
    J Clin Oncol; 1998 Apr; 16(4):1287-93. PubMed ID: 9552027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
    Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
    Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
    Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
    Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.
    Ozols RF; Ihde DC; Linehan WM; Jacob J; Ostchega Y; Young RC
    J Clin Oncol; 1988 Jun; 6(6):1031-40. PubMed ID: 2453619
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
    Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
    Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.
    Rimmer Y; Chester J; Joffe J; Stark D; Shamash J; Powles T; White J; Wason J; Parashar D; Armstrong G; Mazhar D; Williams MV
    Br J Cancer; 2011 Sep; 105(6):766-72. PubMed ID: 21847130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A case of pneumomediastinum during BEP (bleomycin, etoposide, cisplatin) chemotherapy for testicular cancer].
    Noguchi G; Ota J; Ishigaki H; Onuki T; Kato Y; Moriyama M
    Hinyokika Kiyo; 2013 Aug; 59(8):545-9. PubMed ID: 23995535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of good risk germ-cell tumours.
    Troost MM; Sternberg CN; de Wit R
    BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
    J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment Results of Extracranial Malignant Germ Cell Tumor with Regimens of Cisplatin, Vinblastine, Bleomycin or Carboplatin, Etoposide, and Bleomycin with Special Emphasis on the Sites of Vagina and Testis.
    Hou JY; Liu HC; Yeh TC; Sheu JC; Chen KH; Chang CY; Liang DC
    Pediatr Neonatol; 2015 Oct; 56(5):301-6. PubMed ID: 25769700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of 129 patients with advanced and recurrent malignant ovarian germ cell tumor].
    Hong W; Zhang R; Liu L
    Zhonghua Fu Chan Ke Za Zhi; 1998 Jan; 33(1):35-7. PubMed ID: 10682456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
    Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
    J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
    Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
    Tscherry G; Jacky E; Jost LM; Stahel RA
    Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
    Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary yolk sac tumor of the omentum: a case report and literature review.
    Haibin Z; Yue J; Yaxian X
    Eur J Gynaecol Oncol; 2010; 31(6):682-4. PubMed ID: 21319517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lung fibrosis 10 years after cessation of bleomycin therapy.
    Tashiro M; Izumikawa K; Yoshioka D; Nakamura S; Kurihara S; Sakamoto N; Seki M; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Hayashi T; Fukushima K; Tashiro T; Kohno S
    Tohoku J Exp Med; 2008 Sep; 216(1):77-80. PubMed ID: 18719341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of chemotherapy with bleomycin, etoposide, and cis-platinum (BEP) on rat sperm chromatin remodeling, fecundity and testicular gene expression in the progeny.
    Maselli J; Hales BF; Robaire B
    Biol Reprod; 2013 Oct; 89(4):85. PubMed ID: 23986570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.